Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,495 across all filing types
Latest filing 2016-07-27 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - TPIAO RECEIVED MARKETING AUTHORIZATION FROM PIC/S MEMBER UKRAINE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the receipt of marketing authorization for a product (TPIAO) in Ukraine. It is not a financial report, regulatory filing, or any form of detailed financial or management report. The document is relatively short (3092 characters) and serves as a corporate announcement about a regulatory approval related to product marketing. It does not contain financial data, management discussion, or voting results. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement, which corresponds to Regulatory Filings (RNS).
2016-07-27 English
VOLUNTARY ANNOUNCEMENT - MEDICINE FOR COLORECTAL CANCER IS APPROVED FOR CLINICAL TRIAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the approval of a clinical trial for a pharmaceutical product. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial statements. The content is an announcement of a clinical trial approval, which is a regulatory or corporate announcement but not a financial report or detailed regulatory filing. The document length is 4526 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-07-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/06/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions during the month. The content focuses on changes in share capital and securities, including issuance, exercise of options, and warrants. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing reporting monthly share capital movements to the exchange, consistent with a Major Shareholding Notification or Share Issue/Capital Change. Given the detailed share capital movements and issuance data, the best fit is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a substantive report on capital changes.
2016-07-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/06/2016. It details movements in authorised and issued share capital, including ordinary shares, preference shares, share options, warrants, convertibles, and other share-related transactions. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital changes and movements for a specific month. It does not contain financial statements, earnings data, management discussion, or audit information. It is not an announcement of a report but a detailed monthly regulatory filing about share capital movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2016-07-04 English
FINAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2016
Annual Report Classification · 100% confidence The document is a detailed financial report containing consolidated final results for the year ended 31st March 2016, including comprehensive financial statements such as profit or loss, comprehensive income, financial position, segment information, and notes on accounting policies. It references Hong Kong Financial Reporting Standards and includes extensive financial data and analysis for the full fiscal year. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an official yearly report covering company activity and full financial performance, which corresponds to an Annual Report (10-K equivalent) filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2016
2016-06-30 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, specifically detailing changes in issued share capital and share buybacks. It includes information about the number of shares issued, share repurchases, and related notes referencing the Listing Rules of The Stock Exchange of Hong Kong Limited. The content focuses on reporting changes in share capital and repurchases, which aligns with announcements regarding share issues or capital changes. The document is about disclosing changes in issued share capital and share buybacks, not a full financial report or earnings release. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length is 6034 characters, which is sufficient to contain substantive disclosure rather than just an announcement of a report publication or a certification, so it is not RPA or RNS.
2016-06-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.